Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1961-1980 of 2,251 trials

Advanced Non-Small Cell Lung Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced non-small cell lung cancer. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Pancreatic Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced pancreatic cancer to see how well it works and how safe it is. This trial aims to evaluate its effectiveness and side effects compared to standard treatments.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Cystic Fibrosis: Inhaled Teicoplanin Study

We are evaluating the safety and tolerability of inhaled Teicoplanin for cystic fibrosis patients with persistent Staphylococcus aureus infections. The study aims to see if it can improve lung function and reduce infection levels.

Cystic Fibrosis with Staphylococcus Aureus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Chronic Urticaria: Briquilimab Study

We are studying the long-term safety and effectiveness of briquilimab in people with chronic urticaria. This trial includes participants from earlier studies to see how well the treatment works over time.

Chronic UrticariaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

High-Risk Melanoma: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab in patients with high-risk melanoma who have no signs of spread. The goal is to see if this treatment can improve outcomes before surgery.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Soft Tissue Sarcoma: Pembrolizumab with Radiotherapy

We are studying whether adding pembrolizumab to radiotherapy before and after surgery helps patients with high-risk localized soft tissue sarcoma live longer without disease recurrence. This trial compares this approach to standard treatment with radiotherapy and surgery alone.

High-Risk Soft Tissue Sarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOrthopedics and Traumatology

ADPKD Treatment: Metformin vs. Tolvaptan

We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Nephrotic Syndrome: Ketoanalogues for Muscle Preservation

We are studying a new treatment to help prevent muscle loss in patients with nephrotic syndrome. This trial will assess its safety and how it may improve overall health and quality of life.

Protein-Energy Wasting in Nephrotic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

ANCA-Associated Vasculitis: Rituximab Treatment Study

We are comparing a combination of rituximab and cyclophosphamide to standard treatment for achieving remission in severe ANCA-associated vasculitis. The trial also looks at how different ways of giving rituximab can help maintain remission.

ANCA-Associated Vasculitis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Kidney Health After Transplant: Dapagliflozin Study

We are studying how dapagliflozin affects kidney structure and inflammation in patients with impaired kidney function one year after transplantation. This research may help us understand better treatments for kidney transplant recipients.

Chronic Kidney Disease (CKD)3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Infant Immunity to Whooping Cough: Maternal Vaccination Study

We are studying how vaccines given to pregnant women affect their infants' immunity to whooping cough. Our goal is to find out what factors influence the transfer of protective antibodies from mothers to their babies.

Whooping Cough>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsInfectious DiseasesInternal Medicine

Atherosclerosis: Psilocybin Therapy Study

We are exploring if psilocybin-assisted therapy can help reduce plaque buildup in patients with ischemic heart disease. This study will also look at safety and changes in plaque characteristics over time.

Stable Ischemic Heart DiseaseEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule

We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.

Small Intestine Neuroendocrine Tumor>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Small Cell Lung Cancer: MK-6070 and Ifinatamab Deruxtecan Study

We are studying the safety and effectiveness of MK-6070 combined with ifinatamab deruxtecan in people with advanced small cell lung cancer. This trial aims to find better treatment options for those whose cancer has returned or is hard to treat.

Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Septic Shock: Comparing Sodium Lactate and Saline Solutions

We are studying how two different intravenous fluids affect blood flow and acid-base balance in patients with septic shock. This research may help improve treatment options for this serious condition.

Septic Shock>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Long COVID: Fibroblast Activity Study with [68Ga]FAPI PET/CT

We are investigating if patients with ongoing long COVID symptoms have higher fibroblast activity than those who have recovered. This may help us understand the underlying causes of long-term health issues after COVID-19.

Long COVIDConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Cardiac AL Amyloidosis: PET/CT Imaging Study

We are studying a new non-invasive imaging method to diagnose cardiac AL amyloidosis in patients with a specific type of protein in their blood. This research aims to see if this method is as effective as traditional invasive tests.

Cardiac Amyloidosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Autoimmune Uveitis: Probiotic Supplement Study

We are studying the effects of a probiotic on people with autoimmune uveitis to see if it improves vision and reduces inflammation. The trial will also check the safety of this treatment.

Autoimmune Uveitis1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOphthalmology

Blood Cancer Treatment: SMART101 After Stem Cell Transplant

We are studying the safety and effectiveness of SMART101 for patients with blood cancers after stem cell transplantation. The goal is to see if it helps improve immune recovery and reduce complications.

Allogenic Stem Cell Transplantation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology